metformin vitabalans 1000 mg tabletki powlekane
vitabalans oy - metformini hydrochloridum - tabletki powlekane - 1000 mg
metformax sr combi 100 mg + 1000 mg tabletki o zmodyfikowanym uwalnianiu
teva pharmaceuticals polska sp. z o.o. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 100 mg + 1000 mg
metformax sr combi 50 mg + 500 mg tabletki o zmodyfikowanym uwalnianiu
teva pharmaceuticals polska sp. z o.o. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 50 mg + 500 mg
metformax sr combi 50 mg + 1000 mg tabletki o zmodyfikowanym uwalnianiu
teva pharmaceuticals polska sp. z o.o. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 50 mg + 1000 mg
metformax sr 500 500 mg tabletki o przedłużonym uwalnianiu
teva pharmaceuticals polska sp. z o.o. - metformini hydrochloridum - tabletki o przedłużonym uwalnianiu - 500 mg
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, type 2 - leki stosowane w cukrzycy - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. potrójnej terapii skojarzonej), jako uzupełnienie diety i ćwiczeń fizycznych u pacjentów niedostatecznie kontrolowanych o ich maksymalnej tolerowanej dawki sulfonylomocznika z metforminą i. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
metformax combi 50 mg + 1000 mg tabletki powlekane
teva pharmaceuticals polska sp. z o.o. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki powlekane - 50 mg + 1000 mg
metformax combi 50 mg + 850 mg tabletki powlekane
teva pharmaceuticals polska sp. z o.o. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki powlekane - 50 mg + 850 mg
etform 500 500 mg tabletki powlekane
sandoz gmbh - metformini hydrochloridum - tabletki powlekane - 500 mg
etform 850 850 mg tabletki powlekane
sandoz gmbh - metformini hydrochloridum - tabletki powlekane - 850 mg